Hypophosphatemia With Intravenous Ferric Carboxymaltose Versus Iron Dextran in Women With Iron Deficiency Secondary to Heavy Uterine Bleeding
| Status: | Archived |
|---|---|
| Conditions: | Iron Deficiency Anemia, Women's Studies, Anemia, Metabolic |
| Therapuetic Areas: | Hematology, Pharmacology / Toxicology, Reproductive |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | August 2010 |
A Randomized, Controlled Study to Investigate the Safety and Explore the Mechanism of Hypophosphatemia With Intravenous Ferric Carboxymaltose (FCM) Versus Iron Dextran in Women With Iron Deficiency Secondary to Heavy Uterine Bleeding
The primary objective of this study is to assess the safety of an investigational
intravenous iron (ferric carboxymaltose [FCM]) or an equal dose of iron dextran and explore
the mechanism of hypophosphatemia following administration of FCM or that of an equal dose
of iron dextran when treating women with iron deficiency anemia due to heavy uterine
bleeding (HUB).
We found this trial at
1
site
Click here to add this to my saved trials
